Navigation Links
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Date:8/30/2007

OVATUREtrial.com Launched to Inform Patients with Recurrent Ovarian Cancer

about the OVATURE Clinical Research Study

NEW CANAAN, Conn., Aug. 30 /PRNewswire-FirstCall/ -- A new website has been launched to facilitate recruitment of patients to OVATURE (OVArian TUmor REsponse), a Phase III clinical trial of an investigational ovarian cancer drug phenoxodiol. The goal of http://www.OVATUREtrial.com is to inform ovarian cancer patients about the OVATURE trial, which is actively recruiting patients, and to provide more information about the trial and the investigational drug phenoxodiol. Visitors to the site will find information about the trial including eligibility, trial locations and participating doctors.

Hospitals and treatment centers throughout the United States, Europe and Australia are serving as trial sites, and http://www.OVATUREtrial.com will guide patients to site locations as they begin recruiting. Ovarian cancer patients whose cancer initially responded to chemotherapy, but has since become resistant or refractory to traditional platinum treatments are eligible to participate.

In the U.S. 30 sites are planned and the current trial locations include Yale University School of Medicine in New Haven, Connecticut; the Women's Cancer Center of Nevada in Las Vegas, Nevada; the University of Texas Southwestern Medical Center at Dallas in Dallas, Texas; Providence Hospital and Medical Centers in Southfield, Michigan; Hematology Oncology in Stamford, Connecticut; Gabrail Cancer Center in Canton, Ohio; Northern Virginia Pelvic Surgery Associates in Annandale, Virginia; and Chattanooga GYN Oncology in Chattanooga, Tennessee.

In Australia, the current trial locations include Prince of Wales Hospital and Westmead Hospital in Sydney; Royal Adelaide Hospital, in Adelaide; and Mater Adult Hospital in Brisbane. In E
'/>"/>

SOURCE Marshall Edwards Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015   HeartWare International, Inc . (NASDAQ: ... support technologies that are revolutionizing the treatment of advanced heart ... , is scheduled to present at the Bank of America ... Vegas on Thursday, May 14, 2015, at 10:00 ... of the Company,s presentation at the conference will be available ...
(Date:5/4/2015)... 2015 MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, today ... the Company,s investigational drug candidate ME-344 in cancer ... with a tyrosine-kinase inhibitor (TKI). In addition, a ... potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex ...
(Date:5/4/2015)... 2015 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... for quarter ending March 31, 2015 after market ... host a conference call that day at 5:00 ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
... The University HealthSystem Consortium (UHC) today announced an agreement with Centurion Service ... services. The contract was effective on February 1, 2010 . , ... Centurion, the world,s largest medical auction house with ... assists UHC members in the setup and management of their surplus asset programs ...
... (NYSE: ABT ) will present at the 26th Annual Sanford Bernstein ... York City .  Miles D. White, chairman and chief executive officer, will make ... , , , ... presentation will be accessible through Abbott,s Investor Relations Web site at www.abbottinvestor.com ...
Cached Medicine Technology:University HealthSystem Consortium Selects Centurion Service Group for Equipment and Asset Liquidation Services 2
(Date:5/3/2015)... Metamora, Michigan (PRWEB) May 03, 2015 ... mark on their Facebook page. , Their ... on the many services the Practice has, it’s multiple ... events. , Women’s Excellence has a very strong social ... Pinterest, Instagram and You Tube. , Women’s Excellence ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Leading international ... announced it will be awarding the 2015 Harris Wofford ... and Selemawit Ghebrendrias, are the deserving recipients of the ... global service, Harris Llewellyn Wofford. The two recipients were ... passion for global health. , CFHI is one ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Indiana Fiber ... Provider announces Bank Computer Services, Inc (BCS) has selected ... BCS’ President states, “The technology, service, and working relationship ... like is the local feel you get with IFN. ... managed company; IFN makes local decisions and operates as ...
(Date:5/3/2015)... Missouri (PRWEB) May 03, 2015 ... business that will directly impact your career? The ... designed for dynamic leaders in multinational companies and ... company. In a changing global landscape, differences in ... and relationships. The EMIB program develops the global ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 SpineFrontier, a ... from the FDA to produce and market their new ... can be used in outpatient settings and is compatible ... alternate posterior approach has been extensively researched and refined ... approval to use this approach in conjunction with a ...
Breaking Medicine News(10 mins):Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 3Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2
... prolonged air journeys could expose the passengers to risk ... United Nations //health agency has issued fresh guidelines to ... resistant tuberculosis must postpone any long distance air travel, ... no case of active TB has been identified due ...
... been receiving incessant calls from four groups, which represent ... hepatitis C after receiving contaminated blood products, to reject ... standing issue of insurance. , Health Minister, ... a bill to establish a statutory scheme that would ...
... have announced a new test to identify patients who ... could be at fault is unveiled ,today//. ,An ... their report in the New England Journal of Medicine. They ... these patients could then get the best treatment and will ...
... experts have written an open letter in the Scotsman newspaper ... rumors// that MMR Vaccine was linked to autism. ... the UK could face a serious situation with outbreaks of ... of "any association between MMR and autism" should be effectively ...
... rehabilitation system that can perform a variety of ... cricket captain Dilip Vengsarkar here Tuesday//. ,PrimusRS, ... measure the performance, recovery, and fitness-levels of sportspersons. ... participation in the international sporting arena has sports ...
... reduce the risks associated with erectile dysfunction and other ... School of Public Health (HSPH) revealed a positive correlation ... a negative correlation with regular physical activity and healthy ... the Harvard School of Public Health (HSPH) has found ...
Cached Medicine News:Health News:A New Test Developed to Identify Suspected Bowel Cancer Patients 2Health News:Erectile Dysfunction Linked with Smoking and Obesity – Study Report 2
... somatomedin-C, is a peptide highly dependent on ... activity. IGF-I is transported in serum by ... growth disorders, measurements of IGF-I are a ... secretion. A normal plasma or serum IGF-I ...
... IMMULITE 2500 is a high-throughput immunoassay system ... the IMMULITE 2000 with the important addition ... ,allows assays to be designed for optimal ... ,This allows for critical assays such as ...
... For The Detection Of ... Of C-Peptide Measurement:, ... hypoglycemia , Assisting in ... mellitus , Differentiating insulin ...
... kit is for the quantitative determination of ... the AutoDELFIA Automatic Immunoassay System. C-peptide measurement ... function in patients treated with insulin, to ... diabetes, and various other diagnostic applications in ...
Medicine Products: